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HIV-1 reverse transcriptase (RT) was found to increase the activity of HIV-1 proteinase in vitro and in eukaryotic ells. 
The effect of RT on proteinase activity was dose-dependent and independent of pH or salt concentration. The cleavage of 
sequences corresponding to all the naturally occurring cleavage sites that could be tested in vitro was enhanced. The effect 
of RT on cleavage was greatest at the cleavage site between RT and integrase. The enhancement of viral proteinase activity 
by the virus RT may contribute to regulation of the order and/or efficiency of cleavage at different sites during virus 
replication and maturation. © 1995 Academic Press, Inc. 
INTRODUCTION 
HIV-1 proteinase is expressed within the Gag-Pol 
polyprotein (Kramer et a/., 1986), which is the precursor 
of all viral structural proteins and enzymes, including 
reverse transcriptase (RT). The proteinase is responsible 
for the proteolytic processing of this precursor into ma- 
ture proteins (Graves et aL, 1988; Mous et aL, 1988), a 
process that leads to the formation of infectious virus 
particles (Kohl et aL, 1988, G6ttlinger eta/., 1989; Peng 
eta/., 1989). The proteinase is active within the Gag-Pol 
polyprotein since it cleaves itself out from the polyprotein 
precursor (Debouck et a/., 1987; Giam and Bores, 1988). 
However, very little is known about the activity and sub- 
strate specificity of the Gag-Pol precursor form of the 
proteinase or the effect of other viral proteins on the 
activity and substrate specificity of the mature form of 
the proteinase (which is a 22-kDa dimer) (Katoh et aL, 
1989; Lapatto eta/., 1989; Meek eta/., 1989; N avia eta/., 
1989; Wlodawer eta/., 1989). 
Since RT is expressed within the Gag-Pol polyprotein, 
it is a substrate of the proteinase, and as such it interacts 
directly with the enzyme. The proteinase and the RT are 
the main targets for anti-HIV/AIDS therapy. The interac- 
tion between the RT and proteinase may therefore be 
important not only for understanding the process of viral 
replication and maturation, but also for the development 
of antiviral drugs. 
We have studied the interaction between these two 
enzymes by testing the effect of HIV-1 RT on HIV-1 pro- 
teinase activity. Incubation of purified proteinase with 
purified RT heterodimer efficiently enhanced proteinase 
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activity in vitro. The effect of RT on proteinase activity 
was also studied intracellularly, using a vaccinia T7 ex- 
pression system. Our results show that HIV-1 RT en- 
hances HIV-1 proteinase activity both in vitro and in cell 
culture. The characterization of this enhancement is pre- 
sented and its possible biological function discussed. 
MATERIALS  AND METHODS 
In vitro HIV-1 proteinase activity 
HIV-1 Reverse transcriptase and proteinase were ex- 
pressed in Escherichia coil and purified as previously 
described (Unge et aL, 1990; Bhikhabhai et aL, 1992; 
Goobar eta/., 1991). HIV-1 RT 216 and RT 235 represent- 
ing the first 216 and 235 N-terminal amino acids of HIV- 
1 RT, respectively, were expressed in E. coil and purified 
to homogeneity (Unge et al., 1994; Unge, Bhikhabhai, 
Osterlund, and L0vgren, manuscript in preparation), 
Purified recombinant HIV-1 p24 capsid (CA) protein 
was from MicroGenSys (Merridan, CT, U.S.A.), and was 
kindly provided by Dr. F. Volvovitz (MicroGenSys) and 
Professor B. Wahren (Swedish Institute for Infectious Dis- 
ease Control). Bovine serum albumin (BSA), fraction V, 
No. A-4503, was from Sigma Chemical Co. (St. Louis, 
MO, U.S.A.). 
Proteinase activity was measured as previously de- 
scribed (Goobar et al., 1991) using synthetic octapep- 
tides with sequences corresponding to the naturally oc- 
curring cleavage sites. Cleavage products were analyzed 
and quantified by reverse phase HPLC. HIV-1 proteinase 
was preincubated for 5 min with or without purified HIV- 
1 RT at 37 ° prior to addition of substrate. RT, proteinase, 
and substrates were diluted in activity buffer (50 mM 
NaAc, pH 5.5, 10% glycerol, 2 mM Dq-i-, 1 mM EDTA, and 
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175 mM NaCI, unless otherwise indicated) and incubated 
at 37 ° in the same buffer for the times indicated. For 
measurements of proteinase activity at neutral pH, the 
activity buffer was 75 mM sodium phosphate, pH 7.0, 
10% glycerol, 1 mM D-i-i-, and 1 mM EDTA. Reactions 
were stopped by addition of an equal volume (50 #1) of 
0.2% trifluoroacetic acid followed by heating at 100 ° for 
5 min. The proteinase concentration varied between 5 
and 130 nM. The substrate used was SQNYPIVQ-NH2, 
corresponding to the cleavage site between HIV-1 p17 
matrix protein (MA) and p24 CA, and its concentration 
was 0.8 mM, unless otherwise indicated. The hydrolysis 
of this octapeptide was linear with time up to 50% conver- 
sion to products. 
Inhibition of HIV-1 proteinase activity 
HIV-1 proteinase inhibitors U 75875 (Ashorn et aL 
1990) and Re 31-8959 (Roberts et aL, 1990) were kindly 
provided by Dr. W. G. Tarpley (The Upjohn Co.) and Dr. 
I. B. Duncan (Roche Research Centre), respectively. 
Inhibitors were dissolved in dimethyl sulphoxide 
(DMSO) and dilutions were made in activity buffer con- 
taining 1 M NaCI. The final DMSO concentration in the 
samples was 0.5%. Samples without inhibitors were ad- 
justed to the same DMSO concentration. Purified HIV-1 
proteinase was preincubated with or without purified 
HIV-1 RT and inhibitors for 5 min at 37 ° and reactions 
were started by the addition of the substrate peptide 
SQNYPIVQ-NH2. Samples were incubated for 2 hr at 37 ° 
and reactions were stopped as described above. The 
reaction products were analyzed and quantified by re- 
versed phase HPLC as previously described (Goobar et 
aL, 1991). 
Peptide synthesis 
All peptides were synthesised using t-Boc amino acids 
(Bachem, Bubendorf, Switzerland) and p-methylbenzhy- 
drylamine resin (Fluka, Buchs, Switzerland) according to 
the multiple solid-phase peptide synthesis method 
(Houghten, 1985). Removal of protecting groups from the 
formyl-tryptophane and methionine sulfoxide residues 
was achieved by cleavage with 25% hydrogen fluoride 
(Tam et aL, 1983). The peptides were then cleaved from 
the resin with liquid hydrogen fluoride using a multives- 
sel apparatus (Houghten et aL, 1986). All peptides were 
approximately 90% pure. 
Plasmid constructs 
To generate the HIV-1 proteinase expressing plasmid 
pT7-PR, the proteinase coding sequence was PCR-ampli- 
fled from the HIV-1 clone pHXB2 using the oligonucleo- 
tides, PRATGBSS (5'-CGCGCG-CGAAATGCCTCAGATC- 
ACTC-FI-i-GG-3'), which introduces a translational start 
codon, and PRSTOP (5'-TCACTAAAAATTTAAAGTGCA- 
GCCAATC-3'), which introduces two translational stop 
codons. The PCR product was blunt-end ligated to an 
EcoRV-digested and ClAP-treated pBluescript (KS-) 
plasmid (Stratagene, La Jolla, CA, U.S.A.). 
The HIV-1 proteinase-RT producing plasmid pT7-PR- 
RT, was generated by POR-amplification of the protein- 
ase and RT coding sequences of pHXB2 using the oligo- 
nucleotides PRATGBSS and 6702 (5'-GGATCCCTATAG- 
TAT-FFFCCTGATFCCAGCACTGAC-3'). The PCR product 
was blunt-end ligated to the EcoRV-digested and ClAP- 
treated pBluescript (KS-) plasmid. The p55 Gag produc- 
ing plasmidpT7-55 Gag was constructed by POR-ampli- 
fying the Gag region of pHXB2 using oligonucleotides 
2311 (5'-GGCTTGCTGAAGCGCGCACGGCAAGAGG-3') 
and 7492 (5'-TTA-I-FGTGACGAGGGGTCGTTGCC-3'). The 
PCR product was blunt-end ligated into the EcoRV-di- 
gested and ClAP-treated pBluescript (KS-) plasmid. 
Intracellular HIV.-1 proteinase activity 
All experiments were carried out in HeLa cells grown 
in Dulbecco's modified Eagle's medium (Gibco) supple- 
mented with 10% fetal calf serum (Flow Laboratories, 
Scotland, LIK), 5.3 mM L-glutamine (Flow Laboratories, 
Scotland, UK), and 0.1 mg/ml of each streptomycin 
(Sigma Chemical Co.) and benzylpenicillin (ASTRA, Swe- 
den). Cells were seeded 24 hr before transfection in 60- 
mm plates (Falcon), (Becton-Dickinson, N J, U.S.A.) at a 
density of 5 x 10 ~ cells/plate. 
For measurements of intracellular HIV-1 proteinase ac- 
tivity, HeLa cells were infected with the recombinant vac- 
cinia virus vTF7-3 expressing the bacteriophage T7 RNA 
polymerase (Fuerst et al., 1986), generously provided by 
Dr. B. Moss. Virus was titrated to the maximal dilution 
which would give reproducible expression of p55 Gag 
when transfected with 4 #g/plate of Gag-expressing 
plasmid. Two hours after infection cells were transfected 
with iolasmids by calcium phosphate coprecipitation. The 
amount of DNA transfected was adjusted to 16 #g/plate 
in all samples with pBluescript as carrier DNA. 
Cells were transfected with 4 #g/plate pT7-55 Gag 
alone or cotransfected with different amounts (0.063- 
0.25 fig/plate) of pT7-PR or pT7-PR-RT. Six hours after 
transfection, the cells were washed twice with pho s- 
phate-buffered saline and new medium was added. 
Twenty-four hours after transfection, the cells were har- 
vested in 25 mM Tris, pH 7.4, 75 mM NaCI, 0.5% Triton 
X-100, 0.5% Na-deoxycholate, 0.05% SDS, 0.07 TIU/ml 
Aprotinin (Sigma Chemical Co.). After three freeze/thaw 
cycles, cell extracts were centrifuged at 12,000 g for 15 
min at 4 ° and supernatants transferred to new tubes. 
Sample amounts were adjusted for protein content prior 
to sodium dodecyl sulphate-polyacrylamide gel electro- 
phoresis (SDS-PAGE) and Western blot. 
SDS-PAGE and Western blot 
SDS-PAGE and Western blots were performed ac- 
cording to Sambrook et al. (1989). Samples were sepa- 
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FtG. 1. The concentration-dependent ffect of HIV-1 RT on HIV-1 
proteinase (PR) activity was measured at different concentrations of 
HIV-1 proteinase. Activity is expressed as % cleavage of substrate 
peptide SQNYPIVQ-NHz (0.8 mM) after 2-hr incubation at 37 ° with the 
proteinase in the absence or presence of RT. Values at 128 nM PR 
correspond to the mean + SD of two independent determinations run 
in duplicate. Values at 37 and 5 nM PR are the mean + SD of duplicates 
from single experiments. 
rated on 12% acrylamid, 0.32% bis-acrylamid gels at 150 
V for 1 hr in a Bio-Rad Mini-Protan II apparatus and 
transferred to nitro-cellulose filters (Schleicher & Schuell, 
Dassel, Germany) for 1 hr at 300 mA. After blocking with 
10% nonfat dry milk for 1 hr at 37 ° , filters were rinsed 
briefly and washed for 3 x 5 min in phosphate-buffered 
saline with 0.3% Tween 20. Membranes were incubated 
with 7500-fold diluted anti-p24 CA monoclonal antibody 
EF7 (Hinkula et aL, 1990), a generous gift from Dr. J. 
Hinkula (Swedish Institute for Infectious Disease Con- 
trol) for 1 hr at 37 ° , washed as described above, and 
incubated for 1 hr at 37 ° with 15,000-fold diluted horse 
radish peroxidase-conjugated rabbit immunoglobulins to 
mouse immunoglobulins (Amersham, Sweden). After 
washing as previously described, proteins were detected 
by enhanced chemiluminescence (Amersham, Sweden) 
and exposure to X-ray film (Fuji, RX). 
RESULTS 
Enhancement of HIV-1 proteinase activity by HIV-1 RT 
Purified HIV-1 reverse transcriptase was found to in- 
creases HIV-1 proteinase activity in vitro in a dose-de- 
pendent manner (Fig. 1). The concentration of RT giving 
maximal effect was dependent on the concentration of 
proteinase (Fig. 1), suggesting a direct interaction be- 
tween the proteinase and RT. At the highest proteinase 
concentration used (128 riM), maximal effect was ob- 
served at roughly equimolar concentrations of RT and 
proteinase (Fig. 1). Although the substrate concentration 
is rate limiting at 80% cleavage (Fig. 1), optimal effect 
was observed at the same proteinase/RT ratio even at 
higher substrate concentrations, in the linear range for 
substrate dependence (data not shown). No degradation 
of substrate peptides was observed when they were in- 
cubated with RT alone. Likewise, no degradation of RT 
or proteinase was observed when they were incubated 
together in the absence of substrate, measured by HPLC 
(data not shown). RT was preincubated with proteinase 
for 5 min at 37 ° to allow for association of the proteins 
prior to addition of substrate. The effect of RT on protein- 
ase activity was also observed when reactions were 
started by the addition of substrate immediately after 
mixing ice-cold RT and proteinase (data not shown). 
Proteinase activity was completely inhibited by the 
high affinity HIV-1 proteinase inhibitors U 75875 (Ashorn 
et aL, 1990) and Ro 31-38959 (Roberts et aL, 1990), both 
in the presence and absence of RT. Figure 2 shows the 
results obtained with Ro 31-38959. U 75875 gave similar 
results. 
Proteinase activity was measured for incubation times 
between 10 rain and 2 hr; during this time interval protein- 
ase activity was linear both in the presence and absence 
of RT (Fig. 3). No degradation of proteinase was detect- 
able by silver staining of SDS-PAGE of incubation mix- 
tures, when proteinase was incubated without RT for 2 
hr at 37 ° (data not shown). 
The effect of pH and ionic strength on enhancement 
of HIV-1 proteinase activity by HIV-1 RT 
The optimal conditions for proteinase activity in vitro 
include a high salt concentration (Wondrak et aL, 1991) 
30 
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10' 
0 I~M 0,1 p.M 1 p,M 
Ro 31-8959 concentration 
FtG. 2. Inhibition of HIV-1 proteinase activity by Ro 31-8959 in the 
abscence (-RT) or presence (+RT) of HIV-1 RT (250 nM). Proteinase 
activity is expressed as % cleavage of substrate peptide SQNYPIVQ- 
NH2 (2 mM). The proteinase concentration was 66 nM. 
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FIG. 3. HIV-1 proteinase activity expressed as % cleavage of substrate 
peptide SQNYPIVQ-NH2 (0.8 mM) after different incubation times at 37 ° 
in the absence (-RT) or presence (+RT) of HIV-1 RT (500 nM). The 
proteinase concentration was 17 nM. Values are the mean + SD of 
duplicates of one of three independent determinations that gave similar 
results, 
and a low pH (Darke et aL, 1989; Ido et al., 1991). At 
neutral pH and physiological salt concentration, condi- 
tions encountered in the infected cell, proteinase activity 
in vitro is very low. 
In order to investigate if the enhancement of protein- 
ase activity by RT could occur at neutral pH, and if it was 
dependent on the salt concentration, we compared the 
proteinase activity in the presence and absence of RT at 
different pH's and salt concentrations (Fig. 4). The effect 
of RT on proteinase activity at low salt concentrations 
and low pH is much larger than the increase in protein- 
ase activity observed at high salt concentrations in the 
absence of RT at the same pH (Fig. 4). Both effects are 
roughly additive, indicating that they are independent of 
each other. The fact that RT can enhance proteinase 
activity at 1 M NaCI (Fig. 4), suggests a strong interac- 
tion between the proteinase, or the substrate peptide, 
and RT. 
Approximately the same degree of cleavage was mea- 
sured at neutral pH (7.0) in the presence of RT, as at low 
pH (5.5) in the absence of RT, when measured at low 
ionic strength (/ = 0.18 for pH 7.0 and / = 0.24 for pH 
5.5) (Fig. 4). 
Specificity of the enhancement of HIV-1 proteinase 
activity by HIV-1 RT 
To test the specificity of the enhancement of protein- 
ase activity by RT, we compared the effect of RT with 
that of HIV-1 p24 CA, BSA, and two fragments of HIV-1 
RT corresponding to the first 216 N-terminal amino acids 
(RT 216) or 235 N-terminal amino acids (RT 235) at equi- 
molar concentrations. P24 CA had no significant effect 
on proteinase activity up to 500 nM (Fig. 5A). A significant 
increase of activity was observed at 1 #M p24 where a 
plateau was reached. Even at saturating p24 CA concen- 
trations its effect on proteinase activity was lower than 
that of RT. If the effect of RT on proteinase activity in 
vitro was a bulk effect due to an increase in protein 
concentration in the assay, the higher molar concentra- 
tion needed for p24 CA to obtain a measurable effect 
could be explained by its lower molecular weight. This 
would, however, not explain the differences found at sat- 
urating p24 CA concentrations. To elucidate if the differ- 
ences between p24 CA and RT were due to the differ- 
ences in molecular weight we tested the effect of two 
fragments of RT. RT 216 has a slightly lower molecular 
weight than p24 CA, approximately 23,000 Da, whereas 
R-i- 235 has a slightly larger molecular weight than p24 
CA, approximately 25,000 Da. As shown in Fig. 5A, all 
three proteins had consistently different effects than RT 
on proteinase activity at protein concentrations below 1 
#M. At protein concentrations of 1 #M or above RT 216, 
RT 235, and p24 CA reached the same level of saturation 
which was lower than the level reached with RT. We 
cannot exclude the possibility that there is a bulk effect 
at the higher protein concentrations used here; however, 
the differential effect of p24 CA, RT 216, and RT 235 at 
concentrations below 1 #M shows that there is a specific 
effect of RT and its fragments in this molar range. 
An increase in proteinase activity in the presence of 
BSA has been previously reported (Jordan et al., 1992). 
The effect of saturating BSA concentrations on protein- 
ase activity was much lower than that of RT (Fig. 5B). 
To determine if the effect of RT on proteinase activity 
was substrate dependent, we compared the proteinase 
cleavage of different substrates in the presence and ab- 
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FIG. 4. HIV-1 proteinase activity expressed as % substrate (SQNYP- 
IVQ-NH2 0.8 mM) cleaved after 2-hr incubation at 37 ° at the pHs and 
NaCI concentrations indicated, in the presence (-I- RT) or absence (-RT) 
of HIV-1 RT (107 nM). The HIV-1 proteinase concentration was 56 nM. 
Values are the mean + SD of duplicates of one of three determinations 
which gave similar results. 
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FIG. 5. HIV-1 proteinase activity expressed as % substrate (SQNYPIVQ- 
NH2, 2 mM) cleaved after 2-hr incubation at 37 ° in the absence or pres- 
ence of different concentrations of HIV-1 RT and HIV-1 p24 CA, RT 216 
and RT 235 (A), or BSA (B). The HIV-1 proteinase concentration was 31 
and 34 nM, respectively. Values are the mean + SD of duplicates from 
one of three independent determinations giving similar results. 
sence of RT. All known cleavage sites that could be 
tested in vitro were found to be more efficiently cleaved 
in the presence of RT (Fig. 6), indicating that RT interacts 
with the proteinase itself rather than with the peptide 
substrate. Figure 6 shows the relative effect of RT on the 
cleavage of different sites. Experiments are underway to 
determine whether RT also changes the absolute cleav- 
age efficiency of different sites and thus influences their 
cleavage order. The octapeptide RQANFLGK-NH2 repre- 
senting the cleavage site between the p7 nucleocapsid 
(NC) protein and pl was not cleaved bythe proteinase in 
vitro, neither in the absence nor presence of RT. Similarly, 
cleavage of the octapeptide ARVLAEAM-NH2, represent- 
ing the cleavage site between p24 CA and the p2 spacer 
peptide of the Gag polyprotein, could not be detected in 
the absence or presence of RT under the conditions used 
here. Cleavage of the site between RT and integrase was 
the most enhanced, while the cleavage site between 
proteinase and RT was the least influenced by the pres- 
ence of RT (Fig. 6). 
Intracellular enhancement of HIV-1 proteinase activity 
by HIV-1 RT 
To test whether RT would exert its effect on proteinase 
activity intracellularly, we used the vaccinia T7 expres- 
sion system to measure intracellular proteinase activity. 
Proteinase was expressed with or without the RT se- 
quence in cis and its activity monitored as the processing 
of p55 Gag precursor expressed in trans. Processing was 
analyzed by Western blots using anti-p24 CA monoclonal 
antibody EF7 (Hinkula eta/., 1990). As shown in Fig. 7B, 
expression of proteinase in trans with p55 Gag resulted 
in the processing of p55 Gag precursor to a 41- and a 
24-kDa band. The degree of p55 Gag precursor pro- 
cessing was dependent on the amount of proteinase 
expressing plasmid (pT7-PR) transfected into the cells 
(Fig. 7B). 
The 41-kDa band is probably composed of several 
cleavage intermediates (Gowda et aL, 1989; Mervis et 
al., 1988), and the 24-kDa band corresponds to the p24/ 
p25 CA products. When RT was expressed in cis with 
the proteinase and in trans with p55 Gag (Fig. 7C), larger 
amounts of p24/p25 CA were cleaved. Reproducible re- 
sults were obtained using different plasmid preparations 
and vaccinia vTF7-3 virus stocks. 
RNase H/IN 
RT/RNase H 
PR/RT 
poVPR 
p1/p6 
p2/p7 NC 
p17 MA/p24 CA 
I~ ATIMMQRG-NH2 ~+~- I  
N SQNYPtVQ-NH2 ~ ~  
i 
O 20 40 60 80 
% Cleavage above control 
FIG. 6. The cleavage of peptides corresponding to the different HIV- 
1 Gag-Pol polyprotein cleavage sites was measured after 2-hr incuba- 
tion at 37 ° with 16 nM HIV-1 proteinase in the presence and absence 
of HIV-1 RT (256 nM). Results are presented as the % increase in 
substrate cleavage in the presence of RT as compared to controls, in 
the absence of RT. p17 MA, matrix protein; p24 CA, capsid protein; p7 
NC, nucleocapsid protein; PR, proteinase; RT, reverse transcriptase; 
IN, integrase. Values are mean + SD of duplicates of one of three 
independent determinations which gave similar results. 
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FIG. 7. (A) Schematic representation of plasmid constructs used for 
intracellular proteinase activity measurements. (B) Western blot of ly- 
sates of HeLa cells infected with vaccinia vTF7-3, transfected with pT7- 
55 Gag, and cotransfected with increasing amounts of pT7-PR. (C) 
Western blot of lysates of HeLa cells infected with vaccinia vTF7-3 and 
transfected with pT7-55 Gag, lanes 1, 2, and 3. Lanes 1 and 2 were 
cotransfected with pT7-PR-RT (lane 1) or pT7-PR (lane 2) in equimolar 
amounts. Western blots were developed using an anti-p24 CA mono- 
clonal antibody. Results are from one of four independent transfections 
giving similar results. 
These results show that RT affects the processing of 
the p55 Gag precursor in eukaryotic cells. Moreover, 
these experiments indicate that RT enhancement of pro- 
teinase activity is not a result of the in vitro conditions 
used and that the effect is present at intracellular condi- 
tions of pH, ionic strength, and protein concentration. 
DISCUSSION 
Our resuks show that HIV-1 RT significantly increased 
HIV-1 proteinase activity not only in vitro but also intracel- 
lularly. The degree of enhancement in vitro and the RT/ 
proteinase ratio for maximal enhancement was depen- 
dent on both the proteinase and RT concentration, as 
shown in Fig. 1, suggesting a protein-protein interaction. 
At a proteinase concentration of 128 nM the proteinase/ 
RT ratio for maximal enhancement was approximately 1, 
assuming 100% sp act for both RT and the proteinase 
and molecular weights of 117,000 and 21,500, respec- 
tively. This is in agreement with the intracellular ratio of 
RT to proteinase expressed during virus infection. 
One possible explanation for our in vitro results, is that 
RT stabilizes the proteinase against denaturation (Grant 
eta/., 1992) or autoproteolysis (Strickler eta/., 1989; Rose 
et aL, 1993). However, the reaction rate for the proteinase 
over the incubation times used was linear both in the 
presence and absence of RT. Moreover, no proteinase 
degradationwas detectable by silver staining of reaction 
mixtures during this time in the absence of RT. Also, 
neither BSA nor p24 CA could mimic the effect of RT. 
Finally, the possible in vitro instability of the proteinase 
cannot explain the effect of RT observed in cell culture. 
Another possible explanation for the enhancement 
seen both in vitro and in cell culture is that RT promotes 
the dimerizationof the proteinase (Zhang et al., 1991; 
Kuzmic, 1993; Darke et al., 1994). This cannot be ruled 
out, especially in the vaccinia expression system, where 
proteinase dimerization is a rate limiting step (Luukkonen 
et al., submitted for publication). Several in vitro results 
point though against this being the only effect of RT on 
proteinase activity. First, a shift in the dimerization con- 
stant for the proteinase would affect the cleavage of all 
substrates to the same degree. However, as shown in 
Fig. 6, RT enhanced the cleavage of different substrates 
to different degrees. Second, the effect of RT was additive 
to that of high Salt concentration, a condition that most 
probably affects the dimerization of the proteinase. 
The cleavage that was most enhanced in the presence 
of RT corresponds to the site between the C-terminal 
end of RT p66 and the integrase in the Gag-Pol polypro- 
tein. This cleavage, which is not one of the most effi- 
ciently cleaved by the mature proteinase in vitro (Darke 
et aL, 1988), could in vivo be more efficiently cleaved in 
the presence of RT, allowing for the release of the RT 
p66 peptide from the precursor polyprotein. Interestingly, 
this Pol site is also the most sensitive to mutagenesis 
(Loeb et al., 1989). The lack of cleavage of RQANFKGK- 
NH2 corresponding to the cleavage site between p7 NC 
and pl, is in agreement with previous reports (TOzs6r et 
al., 1991; Wondrak et aL, 1993), showing that a larger 
fragment of the p7 NC protein is needed for proteolytic 
cleavage. The other substrate peptide that did not give 
detectable product levels was ARVLAEAM-NHz, repre- 
senting the cleavage site between p24 CA and p2. This 
is the last site cleaved of the Gag polyprotein precursor 
(Tritch et al., 1991 ) and probably the least efficient cleav- 
age site. Higher proteinase Or substrate concentrations 
or longer incubation times may be needed to obtain de- 
tectable product levels with this substrate. Further exper- 
iments are needed to determine whether the order of 
cleavage of the gag- and pol-gene products is influenced 
by the presence of RT. 
The effect of RT on proteinase activity in HeLa ceils 
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is modest, probably due to the fact that Gag and protein- 
ase are expressed in trans and, while most of the Gag 
precursor is transported to the plasma membrane 
(Kaplan and SwanstrOm, 1991), the proteinase (or pro- 
teinase/RT) most probably remains in the cytosol. Hu et 
al. (1990) reported that a construct that contained the 
entire proteinase gene, together with Gag, would pro- 
cess p55 Gag less efficiently than constructs expressing 
Gag-proteinase-RT or the whole Gag-Pol polyprotein. 
in their system the entire pol gene, or fragments thereof, 
were expressed in cis with the Gag polyprotein, and after 
frameshift, as is the case during virus infection. Indeed, 
the effect of RT on Gag processing seen with their con- 
structs is even more pronounced. 
Karacostas et al. (1993), showed that a block of virus 
assembly caused by overexpression of the Gag-Pol 
polyprotein (i.e., increased intracellular proteinase activ- 
ity), could be partially overcome by shortening of the 
Gag-Pol polyprotein by deletion of most of the reverse 
transcriptase, indirectly implying that RT may have an 
effect on proteinase activity. These results are in 
agreement with ours and further corroborate the effect 
of RT in eukaryotic cells. The effect of RT on proteinase 
may represent a feed back enhancement of enzyme ac- 
tivity by its substrate. Alternatively, the effect of RT may 
reflect he activity of the proteinase within the polyprotein 
precursor or in a processing intermediate. This would be 
analogous to polio virus polyprotein processing, where 
the processing intermediate 3CD containing the se- 
quences for the proteinase and the viral RNA-dependent 
RNA polymerase is the form of the proteinase required 
for complete processing of the capsid protein precursor 
P1 (Ypma-Wong et aL, 1988). RT may also enhance pro- 
teinase activity at a specific stage of virus replication 
and function as a regulatory mechanism for proteinase 
activity. 
Experiments are underway to determine the mecha- 
nism by which RT enhances proteinase activity and its 
role during virus replication. 
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